ArticleJournal for immunotherapy of cancer2020

Hyperprogression to camrelizumab in a patient with esophageal squamous cell carcinoma harboring EGFR kinase domain duplication.

Wei Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.